menu
    • menu
    [{"orgOrder":0,"company":"Dilafor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DF 01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Dilafor AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dilafor AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dilafor AB \/ Undisclosed"},{"orgOrder":0,"company":"Dilafor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DF01","moa":"Uterine contractility","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dilafor AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dilafor AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dilafor AB \/ Undisclosed"},{"orgOrder":0,"company":"Dilafor AB","sponsor":"Liverpool University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Tafoxiparin","moa":"Uterine contractility","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dilafor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dilafor AB \/ Liverpool University","highestDevelopmentStatusID":"4","companyTruncated":"Dilafor AB \/ Liverpool University"}]

    Find Clinical Drug Pipeline Developments & Deals by Dilafor AB

    Menu

    Dilafor AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dilafor AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dilafor AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafoxiparin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Liverpool University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dilafor Initiates Collaboration with Liverpool University to Study the Effect of Tafoxiparin on SARS-CoV-2

                            Details : Liverpool University with Keele University will study Tafoxiparin in order to find an effective treatment of patients who’ve been struck by COVID-19 virus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 17, 2020

                            Lead Product(s) : Tafoxiparin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Liverpool University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dilafor AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dilafor AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF01

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix

                            Details : DF01 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dystocia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2019

                            Lead Product(s) : DF01

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dilafor AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dilafor AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF 01

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arres...

                            Details : DF 01 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 22, 2016

                            Lead Product(s) : DF 01

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth